Addictions and Their Treatment Course Early Bird Rate ends after September 9, 2024 Registration Type Member Early Bird Rate Member Standard Rate Non-Member Early Bird Rate Non-Member Standard Rate Physician/Semi-Retired/Retired $400 $480 $440 $540 Health Professional Student / Fellow / Resident / Trainee $115 $135 $115 $135 **Membership dues must be paid through the live course date in order to qualify for the member rate. ABPN Diplomates receive AAAP Member rates. Email annual-meeting@aaap.org for the promo code.

Friday, September 13, 2024 11:30 AM -11:35 AM Welcome and Introductions 11:35 AM – 12:35 PM General Concepts and Epidemiology Kevin Sevarino, MD, PhD 12:35 PM – 12:40 PM Break– 5 minutes 12:40 PM – 1:40 PM Benzodiazepines: The Hidden Epidemic Richard Ries, MD 1:40 PM – 1:45 PM Break– 5 minutes 1:45 PM – 2:45 PM Stimulant-Related Disorder Steven Batki, MD 2:45 PM – 2:50 PM Break– 5 minutes 2:50 PM – 3:50 PM Tobacco and Nicotine Jill Williams, MD 3:50 PM – 3:55 PM Break– 5 minutes 3:55 PM – 4:55 PM Cannabis Petros Levounis, MD 4:55 PM – 5:00 PM End-of-Day Wrap-Up Saturday, September 14, 2024 11:30 AM -11:35 AM Welcome and Introductions 11:35 AM – 12:35 PM Alcohol David Marcovitz, MD 12:35 PM – 12:40 PM Break– 5 minutes 12:40 PM – 1:55 PM Review of Opioids and Treatment of Opioid Use Disorders* John Renner, MD 1:55 PM – 2:00 PM Break– 5 minutes 2:00 PM – 2:45 PM Urine Drug Testing** Kevin Sevarino, MD, PhD 2:45 PM – 2:50 PM Break– 5 minutes 2:50 PM – 3:50 PM Neurobiology and Genetics Kevin Sevarino, MD, PhD 3:50 PM – 3:55 PM Break– 5 minutes 3:55 PM – 4:55 PM Psychosocial Treatments of the Addictions Edward Nunes, MD >4:55 PM – 5:00 PM End-of-Day Wrap-Up Each live presentation is allocated 45 minutes , followed by 15 minutes of live Q&A .* Presentation allotted 60 minutes, followed by 15 minutes of live Q&A .** Presentation allotted 30 minutes, followed by 15 minutes of live Q&A .

Alcohol Cannabis Benzodiazepines: The Hidden Epidemic General Concepts and Epidemiology Neurobiology and Genetics Review of Opioids and Treatment of Opioid Use Disorders Psychosocial Treatments of the Addictions Stimulant-Related Disorders Tobacco and Nicotine Urine drug testing

On-Demand Topics Co-Morbidity of Substance and Other Psychiatric Disorders Medical Comorbidities in Patients with Substance Use Disorders Emerging Drugs Inequities in Addiction Treatment for Racial and Ethnic Minority Populations Sex and Drugs: Gender Differences in Substance Use Disorders Pain and Addiction Behavioral Addictions Pregnancy and Substance Use Disorders Naloxone Overdose Training Motivational Interviewing Substance Use Disorder in Hospital Settings Forensic Issues in Addiction Substance Use Disorders in the Older Adult Youth with Substance Use Disorders and Attention Deficit Hyperactivity Disorder Suicide and Substance Use Disorders On-Demand Faculty Edward V. Nunes, MD Steven L. Batki, MD Petros Levounis, MD, MA Adina Bowe, MD Kathleen T. Brady, MD, PhD Roger Chou, MD, FACP Timothy W. Fong MD Michelle Lofwall. MD Carla Marienfeld, MD, DFAPA, FASAM Sanchit Maruti, MD, MS Laurence M. Westreich, MD Louis Trevisan, MD Amy Yule, MD

Accreditation and Designation Statements

Accreditation Statement In support of improving patient care, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. Target Audience Statement The field of Addiction changes frequently as new information becomes available. This course presents a broad-based overview of addictions and up-to-date information in the field of addiction. It is recommended for physicians, PA-Cs, nurse practitioners, and other professionals who wish to stay updated on the most recent trends in the addiction field. It is equally relevant to junior faculty and clinicians as well as experienced practitioners and is intended to help psychiatrists prepare for ABPN certification and recertification examinations in Addiction Psychiatry.The activity was designated for learners in the following ways: Physician Designation Statement American Academy of Addiction Psychiatry designates this Other activity (23.5 hours of enduring material and 10 hours of live online) for a maximum of 33.5 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. ABPN Diplomates The American Board of Psychiatry and Neurology has reviewed AAAP's 2024 Addictions and Their Treatment and has approved this program as part of a comprehensive self-assessment program, which is mandated by the ABMS as a necessary component of maintenance of certification. This activity awards 10 Self-Assessment Category 1 CME Credits. The approval period is through June 6, 2026. AAPA Credit Designation Statement PAs may claim a maximum of 33.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit ™ from organizations accredited by ACCME or a recognized state medical society. Nurse Practitioners and Registered Nurses For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit ™ issued by organizations accredited by the ACCME. Health Professionals Designation Statement Participants will receive a Certificate of Attendance stating this program is designated for 33.5 AMA PRA Category 1 Credits ™. This credit is accepted by the AANP. Credits subject to change

Dr. Adina Bowe is originally from Nassau Bahamas. Presently she is an Assistant Professor of Internal Medicine and Psychiatry at West Virginia University Charleston Division /Charleston Area Medical Center. She completed her undergraduate degree at Macalester College in St Paul Minnesota with majors in Neuroscience and Biology and minor in Psychology. She completed medical school training at the University of the West Indies in Kingston Jamaica. She completed residency in Internal Medicine and Psychiatry at West Virginia University. She completed a Fellowship in Addiction Psychiatry at Yale University. She is quadrupled board certified in Internal Medicine, Psychiatry, Addiction Psychiatry and Addiction Medicine.She is currently the Director of the WVU Comprehensive Opioid Addiction Treatment Program Charleston Division. This clinic follows the hub-and-spoke model where Dr. Bowe serves as a mentor in Project ECHO for other clinicians in West Virginia via telemedicine. Dr. Bowe is also a medical advisory board member for CAMC addiction services and is on CAMC’s Substance Use Disorder Task Force. She is also an advisory board member for REACH (Recognizing and Eliminating disparities in Addiction through Culturally informed Healthcare) at Yale University. Most recently she has become a board member for the American Academy of Addiction Psychiatry (AAAP) and chairs the Diversity, Equity and Inclusion committee.Dr. Bowe is a member of the WVU Advocacy and Diversity Action Planning Team (ADAPT) which focuses on advocacy in health care for minority groups and increasing diversity in treatment teams and health care delivery systems of WVU/CAMC. She is also a member of the GME CAMC/WVU Diversity and Inclusiveness committee which is geared towards promoting and implementing diversity, inclusion and equity in the residency programs of this institute. In her role, she has co led faculty and resident training with regards to DI.Her special interests reside in treating medically complexed, dually diagnosed individuals with addiction disorders in rural communities. She is an advocate for the integrated care model of health delivery. Dr. Bowe is an active member of American Academy of Addiction Psychiatry (AAAP), the American Medical Association and the American Psychiatric Association (APA). As she is passionate about integrated care in substance use disorder treatment she has co-led workshops at AAAP and APA that are geared towards training psychiatrists how to engage family physicians and internists in addictions treatment. Dr. Bowe is an ASAM and PCSS MAT trainer for medical facilities in rural West Virginia.In terms of research, she is particularly interested in kratom, methamphetamine and the impact of consult liaison psychiatry on inpatients with substance use disorders. In her spare time she enjoys visiting her family in the Bahamas, hiking and kayaking.

Kathleen T. Brady, MD, PhD

Dr. Brady is an experienced clinical and translational researcher and has been conducting scientific investigations and clinical work in the field of addictions and psychiatric disorders for over 30 years. Her research focuses on pharmacotherapy of substance use disorders, comorbidity of psychiatric disorders and addictions (e.g., posttraumatic stress disorder and bipolar disorder), gender differences and women’s issues in addictions, and the neurobiologic connections between stress and addictions. She has received numerous federal research grants and has published over 300 peer-reviewed journal articles and co-edited 10 books. She is the Vice President for Research at the Medical University of South Carolina. She is the principal Investigator of MUSC’s Clinical and Translational Science Award (CTSA), Principal Investigator of the Southern Consortium Node of the NIDA-funded Clinical Trials Network and Director of MUSC’s Women’s Research Center. Her dedication to furthering research careers has attracted a number of junior investigators and clinicians. She has served at the President of the Association for Medical Education and Research in Substance Use Disorders (AMERSA), the American Academy of Addiction Psychiatry (AAAP) and is currently the President of the International Society of Addiction Medicine (ISAM).

Roger Chou is a Professor in the Departments of Medicine, and Medical Informatics & Clinical Epidemiology at Oregon Health & Science University (OHSU) School of Medicine, and Staff Physician in the Internal Medicine Clinic at OHSU. He has served as Director of the Pacific Northwest Evidence-based Practice Center since 2012. He has authored over 250 peer-review articles, including numerous systematic reviews, and led or participated in clinical guideline development efforts in chronic pain and opioids, addiction, and other topics. His reviews have been used by the American College of Physicians, the Centers for Disease Control and Prevention, the US Preventive Services Task Force, the American Pain Society, and others to develop clinical practice guidelines. As Director of Clinical Guidelines Development for the American Pain Society, he led the development of clinical practice guidelines on methadone safety, use of opioids for chronic pain, and evaluation and management of low back pain. He led a systematic review on benefits and harms of long-term use of opioids that was used to develop the 2016 CDC guideline on use of opioids for chronic pain, for which he served on the steering committee, and led reviews on methadone policy, models of care for medications for treatment of opioid use disorder and use of naloxone to reverse opioid overdose. Dr. Chou serves as a methodologist for several World Health Organization guideline development groups, served as Coordinating Editor of the Cochrane Back and Neck Group, is Senior Editor of the Cochrane Musculoskeletal Group, and serves on the Board of Scientific Counselors of the CDC’s National Center for Injury Prevention and Control.

Dr. Fong is a Professor of Addiction Psychiatry at the Semel Institute for Neuroscience and Human Behavior at UCLA.He is the director of the UCLA Addiction Psychiatry Fellowship, a one-year program that provides clinical training in the management of addictive disorders.He is also the co-director of the UCLA Gambling Studies Program. The purpose of this program is to examine the underlying causes and clinical characteristics of gambling disorder in order to develop effective, evidence-based treatment strategies.Dr. Fong is Director of the Steering Committee to the UCLA Cannabis Research Initiative, a multidisciplinary effort to examine the full impact of cannabis on the body, mind and brain.Finally, he is the Director of the UCLA Sports Psychiatry Service, a multidisciplinary treatment program that manages the psychiatric needs of UCLA student athletes and professional athletes. Scope of Work Creating and delivering continuing education programs for sober and mental health companions Determining best practices for sober and mental health companions

Ayana Jordan, MD, PhD

Ayana Jordan, MD, PhD, an Addiction Psychiatrist, Assistant Professor of Psychiatry in the Department of Psychiatry, and Director of the Social Justice and Health Equity Curriculum, is dedicated to creating spaces and opportunities for more people of color, specifically Black women in academia who are vastly underrepresented. The fundamental message of equity and inclusion has informed her research, clinical work and leadership duties at Yale and beyond. Dr. Jordan is also one of the new Associate Program Directors for the Yale Psychiatry Residency, a large group of 64 physicians providing mental health and addiction services throughout Yale medical systems in the state of CT.She recently became Director of Equity, Diversity and Inclusion for the Justice Community Opioid Innovation Network within the National Institute of Drug (Ab)use, where she’ll be working to improve health outcomes for people with opioid use disorder in the carceral system. Dr. Jordan also serves the medical director of Recognizing and Eliminating disparities in Culturally-informed Healthcare or (REACH), a Substance (Ab)use and Mental Health Services Administration grant, in conjunction with the American Academy of Addiction Psychiatry, geared at increasing the number of addiction specialists from racial and ethnic minority populations who obtain training to provide culturally-informed addiction treatment. Passionate about helping racial and ethnic minorities achieve wellness and recovery from substance use disorders, Dr. Jordan was fully drawn to community-based research. Her goal is to improve outcomes for patients from underrepresented racial and ethnic populations, by involving them in every step of the process, from research to clinical interaction. Dr. Jordan is working on an NIH-funded R01 project to provide a computer based cognitive behavioral therapy program known as (CBT4CBT) within the Black Church, an evidenced based therapeutic modality shown to be effective in decreasing substance use. She is also principal investigator of a faith-based recovery program based in 8 Black and Latinx churches throughout the state of CT.She is elated and inspired to exist in an environment supportive of her vision to work with communities, integrating the cultural and religious aspects of people’s lives, while also addressing structural inequities that impede improved mental health and wellness. She is deeply grateful to be taking care of the most marginalized patients during this time, who are facing extreme challenges in obtaining addiction treatment due to COVID19. Dr. Jordan is the proud recipient of various clinical and research awards and was recently inducted into the Top 40 under 40 society, by her undergraduate alma mater, Hampton University, a historically Black institution.

Dr. Michelle Lofwall, board-certified in psychiatry and addiction medicine, is a Professor in the Departments of Behavioral Science and Psychiatry and the Bell Alcohol and Addictions Endowed Chair at the University of Kentucky (UK). She received her bachelors degree from Northwestern University in Psychology and her MD and Masters in Pathology from Chicago Medical School. She completed internship, psychiatry residency, and a fellowship in behavioral pharmacology from Johns Hopkins University. Currently, she is the medical director of UK’s Robert Straus and First Bridge Clinics, which provide comprehensive opioid use disorder (OUD) treatment within the UK Center on Drug and Alcohol Research. Her passion is in improving the care of patients with addiction, and her research has included evaluation of novel treatments for opioid use disorder (e.g., buprenorphine implants and depot injections), physician training, understanding factors associated with buprenorphine diversion, and improving care of complex patients with OUD and deep-seated infections. She was elected as a Distinguished Fellow of American Society of Addiction Medicine (ASAM) and the American Psychiatric Association, is a past ASAM board member and co-director of the American Academy of Addiction Psychiatry’s annual addiction treatment review course. She has received numerous teaching and mentoring awards and was an expert panel member for SAMHSA’s Treatment Improvement Protocol on Medication Treatment for Opioid Use Disorder and invited speaker to the National Academy of Medicine.

Carla Marienfeld, MD, DFAPA, FASAM

Carla Marienfeld, MD, DFAPA, FASAM is board-certified in psychiatry, addiction psychiatry, and addiction medicine, and she is a Clinical Professor at the University of California San Diego who supports recovery in an evidence based, harm-reduction approach through therapy, motivational interviewing, and medication treatment. Her research involves analysis of electronic medical record data for individuals with substance use disorders. She has authored or co-authored over 35 peer reviewed articles, book chapters, practice guidelines, and invited commentaries, and she edited two books: Motivational Interviewing for Clinical Practice and Absolute Addiction Psychiatry Review: An essential board exam study guide. She has been highly involved in education of colleagues and trainees about addiction psychiatry and effective interventions including buprenorphine treatment and motivational interviewing, and she is the fellowship director for the UCSD Addiction Psychiatry Fellowship. Dr. Marienfeld completed a fellowship in addiction psychiatry and residency training in psychiatry at Yale. During her residency, she was chief resident of psychiatry and founded (and later led) the Yale Global Mental Health Program. She earned a medical degree with honors from Baylor College of Medicine in Houston. She is active in many professional organizations, including the American Society of Addiction Medicine, the American Association of Addiction Psychiatry, and the American Psychiatric Association.Carla Marienfeld, MD, DFAPA, FASAM is board-certified in psychiatry, addiction psychiatry, and addiction medicine, and she is a Clinical Professor at the University of California San Diego. She edited two books: Motivational Interviewing for Clinical Practice and Absolute Addiction Psychiatry Review: An essential board exam study guide. She has been highly involved in education of colleagues and trainees, and she is the fellowship director for the UCSD Addiction Psychiatry Fellowship. Dr. Marienfeld completed a fellowship in addiction psychiatry and residency training in psychiatry at Yale, and her medical degree with honors is from Baylor College of Medicine in Houston.

Sanchit Maruti, MD, MS

Dr. Sanchit Maruti, MD, MS, is the Medical Director of the UVM Medical Center (UVMMC), Addiction Treatment Program and the In-patient Psychiatry Service at UVMMC. He is also an Assistant Professor of Psychiatry at the Larner College of Medicine at the University of Vermont.Dr. Maruti received his MD degree from the University of Vermont College of Medicine where he was awarded an Albert Schweitzer Fellowship. He completed his residency training in Psychiatry at the UVMMC and served as Chief Resident during his final year. He was recognized as the UVMMC Resident of Year and received the Arnold P. Gold Award for Humanism and Excellence in Clinical Teaching. He completed Fellowship training in Addiction Psychiatry at the Massachusetts General Hospital and Harvard Medical School.Dr. Maruti’s clinical focus is on working with acutely ill patients and those with co-occurring disorders. His research interests are in the areas of risk assessment and quality improvement. He has worked with national experts on the revision of the national buprenorphine waiver course. He is the Course Director for the American Academy of Addiction Psychiatry (AAAP) annual Addictions and Their Treatment Course. Additionally, he serves on the Board of Directors of the AAAP.

Dr. Trevisan is a Board Certified, Addiction and Geriatric Psychiatrist. He earned his medical degree from Oregon Health Sciences University in Portland, Oregon in 1989. He then completed his Residency in Psychiatry at Yale New Haven Hospital where he was a Laughlin Fellow. He completed a VA funded Fellowship in Addiction in 1994. Following this Dr. Trevisan served as an attending at the VA Connecticut Healthcare System. He started an Ambulatory Detoxification Clinic and served as the medical director of a 24-bed inpatient rehabilitation unit. Over the ensuing 25 years Dr. Trevisan has served as an SUD/Alcohol Disorders researcher, clinician-educator in the Yale Department of Psychiatry and as a Quality Improvement innovator. Dr. Trevisan was recognized for his work educating Yale Medical Students with a Roeske Award in 2012.Dr. Trevisan served as an administrator in the VA Health Care System as Associate Director of the Psychiatry Service at VA Connecticut, and Mental Health Service Line Director for VISN 1, VA New England. He recently served as the Director, Center for Substance Abuse Treatment at SAMHSA.Currently he is a Clinical Professor of Psychiatry at Creighton University School of Medicine and Associate Professor of Psychiatry, Adjunct at Yale University School of Medicine.

Laurence M. Westreich, MD

Laurence M. Westreich, MD is a psychiatrist who specializes in the treatment patients diagnosed with Substance Use Disorders (SUDs), and those dually diagnosed with SUDs and mental disorders. After receiving a bachelor’s degree in English Literature from Northwestern University, he graduated from the University of Minnesota School of Medicine. Following an internship in Internal Medicine at the Hennepin County Medical Center in Minneapolis, Minnesota, Dr. Westreich completed a residency in Psychiatry at New York’s Beth Israel Medical Center and a two-year fellowship in addiction psychiatry at New York University/Bellevue Hospital. He is board – certified in general psychiatry, addiction psychiatry, and forensic psychiatry. Dr. Westreich is Associate Professor of Clinical Psychiatry in the Department of Psychiatry, New York University School of Medicine, and the author of Helping the Addict you Love (Simon and Schuster, 2007), and A Parent’s Guide to Teen Addiction (Skyhorse Publishing, 2017). In his professional practice, Dr. Westreich treats addicted and dually diagnosed individuals, and serves as a consultant in forensic matters, especially drug testing, child custody disputes, and disability. Dr. Westreich is Past President of the American Academy of Addiction Psychiatry and serves as Consultant on Behavioral Health and Addiction to the Commissioner of Major League Baseball.

Dr. Amy Yule is board certified in adult, child, and addiction psychiatry. She is the Director of Adolescent Addiction Psychiatry at Boston Medical Center and an Assistant Professor at the Boston University School of Medicine. Dr. Yule works with youth with substance use disorders and co-occurring psychiatric disorders as well as their family in a multidisciplinary outpatient clinic. She also has NIH funding to examine interventions to prevent substance use disorders in youth with psychiatric disorders. Lastly, Dr. Yule is the co-chair of the Women in Addiction Psychiatry Interest Group for the American Academy of Addiction Psychiatry.

2024 Addictions and Their Treatment Course

Thank you for attending the 2024 course on September 13 – 14, 2024.

On-Demand Course now available!

This on-demand version offers 37.5 CE and 10 self-assessment credits. It costs $500 for AAAP members and ABPN Diplomates and $600 for non-members. Trainees who are AAAP Members (Join for FREE) can purchase this course for $150 (email [email protected] for discount code). *Bulk registration available for Fellowship Directors. Email [email protected] for more information.

View On-Demand Course

View Disclosure to Learner’s Statement ›

Course Topics May Include

Co-Morbidity of Substance and Other Psychiatric Disorders
Medical Comorbidities in Patients with Substance Use Disorders
Emerging Drugs
Inequities in Addiction Treatment for Racial and Ethnic Minority Populations
Sex and Drugs: Gender Differences in Substance Use Disorders
Pain and Addiction
Behavioral Addictions
Pregnancy and Substance Use Disorders
Naloxone Overdose Training
Motivational Interviewing
Substance Use Disorder in Hospital Settings
Forensic Issues in Addiction
Substance Use Disorders in the Older Adult
Youth with Substance Use Disorders and Attention Deficit Hyperactivity Disorder
Suicide and Substance Use Disorders

Target Audience

The field of Addiction changes frequently as new information becomes available. This course presents a broad-based overview of addictions and up-to-date information in the field of addiction. It is recommended for physicians, PA-Cs, nurse practitioners, and other professionals who wish to stay updated on the most recent trends in the addiction field. It is equally relevant to junior faculty and clinicians as well as experienced practitioners and is intended to help psychiatrists prepare for ABPN certification and recertification examinations in Addiction Psychiatry.

Educational Objectives

At the conclusion of this activity, participants should be able to:

Describe new advances in pharmacotherapy and psychotherapy of substance use disorders.
Discuss the epidemiology of substance use disorders and their co-occurrence with other psychiatric disorders and review current recommended approaches for concurrent treatment of substance use disorders and other mental health disorders.
Describe the role of genetics in the risk for developing alcohol and other substance use disorders.
Identify the major neurobiological pathways involved in substance disorders.
Identify the molecular mechanisms that are altered following substance use disorder.
Review strategies for screening, brief intervention, and referral to treatment in the context of motivational interviewing.
Review current treatment guidelines and how to utilize them in clinical practice.
Describe special considerations for substance use diagnosis and treatment for women, underrepresented racial and ethnic minorities, youth, older adults, hospitalized patients, and patients with comorbid health conditions.

Presenters

Steven L. Batki, MD

Steven L. Batki, MD Dr. Batki is Professor, Department of Psychiatry and Behavioral Sciences at the Weill Institute for Neurosciences at the University of California, San Francisco (UCSF) School of Medicine and Chief of the AddictionRecovery Treatment Services (ARTS) at the San Francisco Veterans Affairs Health Care System (SFVAHCS).

Dr. Batki directs the UCSF/SFVAHCS Addiction Research Program and is senior consultant to the UCSF/SFVAHCS Addiction Psychiatry Fellowship Program.Previously, he served as Director of the Division of Substance Abuse and Addiction Medicine at San Francisco General Hospital.

Dr. Batki works in addiction research, training, and clinical services. His research focuses on the pharmacological and neurobehavioral treatment of addiction and co-occurring psychiatric and medical disorders in Veterans. He has conducted VA, DoD, NIDA, and NIAAA-fundedresearchaimedto improve the treatment of cocaine, and methamphetamine use disorders as well as alcohol and opioid use disorders. Much of his work has focused on Veterans and other patients with co-occurring medical disorders such as HIV, Hepatitis C, and TB, and co-occurring psychiatric disorders including PTSD, serious mental illness, and the effects of traumatic brain injury (TBI).

Petros Levounis, MD, MA

Petros Levounis, MD, MA, serves as professor and chair of the Department of Psychiatry and associate dean at Rutgers New Jersey Medical School. He is also the chief of service at University Hospital in Newark, New Jersey, director of the Northern New Jersey Medication Assisted Treatment Center of Excellence, and president-elect of the American Psychiatric Association. Dr. Levounis came to Rutgers from Columbia University where he served as director of the Addiction Institute of New York from 2002 to 2013.

Dr. Levounis is a Phi Beta Kappa graduate of Stanford University where he studied chemistry and biophysics before receiving his medical education at Stanford University School of Medicine and the Medical College of Pennsylvania. During medical school, he researched the effects of social class on patient-physician relationships in Oxford, England, and received an MA degree in sociology from Stanford. In 1994, he moved to New York City to train in psychiatry at the New York State Psychiatric Institute of Columbia University. He graduated from Columbia earning the National Institute of Mental Health Outstanding Resident Award and went on to complete his fellowship in addiction psychiatry at New York University.

Dr. Levounis has written numerous articles, monographs, and book chapters; has lectured extensively on addiction topics throughout the United States and abroad; and has been interviewed by CBS, ABC, NBC, CNN, FOX, The Martha Stewart Radio Show, The New York Times, and The Washington Post, among others.

Dr. Levounis has served on the boards of the American Society of Addiction Medicine (ASAM) and the American Board of Addiction Medicine, and from 2005 to 2009 chaired the national Committee on Addiction Treatment of the American Psychiatric Association (APA). Dr. Levounis is a Betty Ford Scholar, a recipient of the Association of Gay and Lesbian Psychiatrists’ Distinguished Service Award and the ASAM Educator of the Year Award, and a distinguished fellow of the APA and ASAM. In 2017, he was elected as an honorary member of the World Psychiatric Association.

Dr. Levounis has published fourteen books including the self-help paperback “Sober Siblings: How to Help Your Alcoholic Brother or Sister—and Not Lose Yourself,” the textbook of “Substance Dependence and Co-Occurring Psychiatric Disorders,” “Motivational Interviewing for Clinical Practice,” “The Behavioral Addictions,” “Becoming Mindful,” “LGBTQ Mental Health: The Spectrum of Gender and Sexuality,” “Office-Based Buprenorphine Treatment of Opioid Use Disorder,” now in its second edition, and “Technological Addictions.” Dr. Levounis is currently working on the first textbook of Nature Therapy, which is going to be available in 2023. His books have been translated into French, German, Hungarian, Japanese, Korean, Portuguese, and Spanish.

Dr. Levounis is married to actor Lukas Hassel and lives in New York City.

David Marcovitz, MD

David Marcovitz, MD Dr. David Marcovitz is a board-certified general and addiction psychiatrist at Vanderbilt University Medical Center and the Director of the Division of Addiction Psychiatry in the Department of Psychiatry and Behavioral Sciences. He helped launch the Vanderbilt University Hospital Addiction Consult Service and transitional outpatient Bridge Clinic at VUMC. He also serves as the Principal Investigator for the state-funded Middle TN Opioid Addiction Treatment Hub at Vanderbilt. While completing his addiction psychiatry fellowship at Partners Healthcare / Harvard Medical School, he also worked as a staff psychiatrist receiving additional mentored training in collaborative care in the IMPACT Model at Partners Healthcare in Boston, MA. He is an experienced educator, delivering formal and informal didactics on various addiction-related topics to medical students, residents, fellows and colleagues. He has served as the senior trainer for Tennessee supporting the federally-funded Opioid Response Network to help build addiction treatment capacity across TN. Dr. Marcovitz’ teaching at the regional and national level has focused on models of collaborative care with internal medicine and other specialties and disciplines in addiction treatment in both the inpatient and outpatient setting. He has also presented at national meetings on novel teaching methods and outcome measures in addiction psychiatry. He has published on addiction education methods as well as research at the intersection of treatment of opioid addiction and community mutual help. Dr. Marcovitz serves on the board of directors for the American Academy of Addiction Psychiatry (AAAP).

More information can be found here: https://www.vumc.org/psychiatry/person/david-marcovitz-md

Edward V. Nunes, MD

Edward V. Nunes, MD Dr. Nunes is Professor of Psychiatry at Columbia University Medical Center and New York State Psychiatric Institute (NYSPI), Multiple PI of the Greater New York Node of the NIDA Clinical Trials Network (CTN), and Co-Director of the CHOSEN Center at Columbia University. He is a practicing psychiatrist Board Certified in Addiction Psychiatry and Addiction Medicine. He has devoted his career to research on the treatment of opioid, cocaine and other substance use disorders and is nationally and internationally recognized for his work on the evaluation and treatment of co-occurring depression and other psychiatric disorders among patients with substance use disorders and the development of pharmacological and behavioral treatments for substance use disorders, as well as for his work in the CTN testing the effectiveness of behavioral and pharmacological treatments in community-based treatment settings. Dr. Nunes has extensive experience with the design, conduct and analysis of clinical trials of treatments for opioid use disorder, including technology-based interventions and extended-release injections and implants of buprenorphine and naltrexone.

John A. Renner, Jr., MD

John A. Renner, Jr., MD Dr. Renner is Professor of Psychiatry, Boston University School of Medicine, and Associate Chief of Psychiatry for the VA Boston Healthcare System. He graduated from Yale University and Case University School of Medicine and completed his psychiatric residency at the Tufts- New England Medical Center. In 1969, Dr. Renner served as a psychiatrist with the US Navy in Vietnam, and since 1979 he has been working at the Boston VA in their outpatient addiction treatment program. In addition to his clinical activities at the VA, he is Associate Director of the Boston University Medical Center General Psychiatry Residency Program and Director of their Addiction Psychiatry Residency.

Dr. Renner has written and lectured extensively on the treatment of alcoholism and drug addiction. He is a member and former chair of the American Psychiatric Association Council on Addiction Psychiatry, former chair of the APA Council on Adult Psychiatry and former Chair of the APA Expert Advisory Panel on Addiction Psychiatry. In 2018, Dr. Renner co-edited the 2nd edition of the APA Handbook of Office-Based Buprenorphine Treatment for Opioid Use Disorder. He is Past-President of the Board of Directors of the American Academy of Addiction Psychiatry, and a member of the Data Safety Monitoring Board for the Clinical Trials Network of the National Institute on Drug Abuse, a member of the Clinical Advisory Committee of the Physician Health Service of the Massachusetts Medical Society, a Consultant to the Department of Psychiatry, Massachusetts General Hospital, and a member of the faculty of the Harvard Medical School Division on Addictions.

Richard K. Ries, MD

Richard K. Ries, MD, is Professor of Psychiatry, and Director of the Addictions Division in the Department of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine in Seattle, Washington, and Director of the Addiction Treatment services at Harborview Medical Center in downtown Seattle. Dr. Ries received his undergraduate degree from Stanford, medical degree from Northwestern Medical School and completed his psychiatric residency at the University of Washington, Seattle, where he was Chief Resident.

Dr. Ries is board-certified in Psychiatry by the American Board of Psychiatry and Neurology with Added Qualifications in Addiction Psychiatry, and the American Board of Addiction Medicine. A Distinguished Fellow of the American Psychiatric Association and a Fellow of the American Society of Addiction Medicine, he is on the editorial board and a reviewer for several scientific journals and has been involved with numerous research grants from the National Institute of Health. In addition he has been active in both studying and treating persons with opioid use disorders, with involvement in SAMHSA grants and the Harborview Addictions program opioid treatment tracks. He has been senior editor of the key reference text: Principles of Addiction Medicine (editions IV and V, published by the American Society of Addiction Medicine, and a noted expert in the field of Addictions, Suicide and other Co-occurring Disorders. Dr Ries works clinically with patients with complex mental, medical and addiction disorders at Harborview Medical Center in downtown Seattle. He has often been listed as one of the Best Doctors in Seattle by Seattle Magazine, including 2018, 2019, and 2020.

Kevin A. Sevarino, MD, PhD

Kevin A. Sevarino, MD, PhD Dr. Sevarino earned his MD, CM at McGill Faculty of Medicine and PhD in molecular biology at the University of Connecticut Health Center. After an internship in Internal medicine, he trained in psychiatry in the dual clinical/basic research tract at the Yale University School of Medicine. For six years thereafter, he was PI on NIH grants examining neurobiological mechanisms underlying cocaine dependence, and since then has transitioned to being a clinician-educator who remained active in clinical research as a member of the MIRECC VA Team in studies examining new treatments for substance use disorders. He was Medical Director of the Newington Mental Health Care Firm, Connecticut VA Healthcare System from Dec. 2004 through Aug. 2017. He was consulting psychiatrist to Gaylord Hospital, Wallingford from 1999 – 2009, and again 2017-2023. He now works as per diem psychiatrist at Hartford Healthcare – Rushford. His particular expertise is in treatment of the dually-diagnosed and non-opiate pharmacological management of chronic pain. He is Associate Clinical Professor of Psychiatry, Yale University School of Medicine. He was subspecialty certified in Psychosomatic Medicine by the American Board of Psychiatry and Neurology from 2009 - 2019, in Addiction Medicine by the American Board of Addiction Medicine from 2010 - 2020, and currently in Addiction Medicine by the American Board of Preventative Medicine. Dr. Sevarino serves as Medical Director for the American Academy of Addiction Psychiatry (AAAP), and is a past president of that organization. He was Course Director for the AAAP Board Review Course in Addictions, which developed into the Addictions and Their Treatment Course, from 2007 - 2015. He currently co-directs AAAP’s Advanced Addiction Psychopharmacology course.

Jill M. Williams, MD

Jill M. Williams, MD, is Professor of Psychiatry and Director of the Division of Addiction Psychiatry at the Rutgers University-Robert Wood Johnson Medical School in New Brunswick. She also holds faculty appointments at the Cancer Institute of New Jersey and the Rutgers Center for Alcohol Studies. The focus of Dr. Williams work has been in addressing tobacco in individuals with mental illness or other addictions through treatment and systems interventions. She is Medical Director for the TCTTAC Program in NYC, in collaboration with Center for Practice Innovation at Columbia University. In 2015 she was the recipient of the Remarkable Achievement Award of the NJ Psychiatric Association. She is past Chair and current member of the APA Council on Addiction Psychiatry.